Esperion Therapeutics, Inc.
ESPR
$2.18
-$0.01-0.46%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 79.45% | -166.30% | 62.16% | 28.43% | -24.01% |
| Total Depreciation and Amortization | 170.00% | -- | 350.00% | 0.00% | -80.39% |
| Total Amortization of Deferred Charges | 85.52% | 59.95% | -60.09% | 4.68% | 4.74% |
| Total Other Non-Cash Items | -88.58% | -64.20% | -49.82% | -58.73% | 307.28% |
| Change in Net Operating Assets | -426.35% | 155.17% | -638.76% | -288.78% | -149.20% |
| Cash from Operations | -336.11% | -142.04% | 5.68% | -82.79% | 70.89% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -100.44% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -68.58% | -- | -- | -- | 110.03% |
| Repurchase of Common Stock | -- | -- | -- | 100.00% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -100.00% | -28.60% | 3,276.86% | -124.28% | 8,779.66% |
| Cash from Financing | 109.49% | -108.28% | 682.73% | -110.92% | -3,811.12% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 23.41% | -120.87% | 100.14% | -88.63% | -479.18% |